News >

Pembrolizumab Plus SBRT Active in Advanced Solid Tumors

Jason Harris
Published: Friday, Feb 16, 2018

Jason J. Luke, MD, FACP

Jason J. Luke, MD, FACP
The addition of pembrolizumab (Keytruda) to stereotactic body radiotherapy (SBRT) induced an objective response rate of 13.2% among patients with advanced solid tumors, according to a phase I study published in the Journal of Clinical Oncology.

= .0005).
Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors [published online February 13, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.76.2229.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication